At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 726 enrolled
Drug / intervention
GSK investigational FluNG vaccine GSK2186877A, aged lot +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.
In Brief
A Phase 3 clinical trial evaluating GSK investigational FluNG vaccine GSK2186877A, aged lot and GSK investigational FluNG vaccine GSK2186877A, fresh lot for Influenza. Completed, enrolled 726 participants across 6 sites in 2 countries.
Detailed Summary
The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesEstonia, Slovakia
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartJul 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedJul 13, 2009
Enrollment StartJul 30, 2009
Primary CompletionOct 5, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.0 years ago
Interventions
GSK investigational FluNG vaccine GSK2186877A, aged lotbiological
Single dose, intramuscular injection
GSK investigational FluNG vaccine GSK2186877A, fresh lotbiological
Single dose, intramuscular injection